Contents 3 min read
Claim and source comparison
Compared abstracts of Stites 2006, Tamakoshi 2023 and the 2024 mixture trial, Nakano 2012’s publisher abstract and EFSA 2017’s scope/safety sections. This limited reading is not comprehensive clinical, independent medical or expert translation review.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Animal study
Stites et al. (2006) studied dietary PQQ and liver mitochondrial amount and function, particularly in developing mice; some measurements changed with a PQQ-deprived diet.
Mouse liver and a special-diet model do not demonstrate increased mitochondria or BDNF in the human brain. This experiment does not establish human PQQ deficiency, an essential nutrient requirement or cognitive benefit.
Source 1 · Abstract read
Uncontrolled human intervention study
Nakano et al. (2012) studied self-reported stress, fatigue and sleep in an open-label trial of 17 adults taking 20 mg/day PQQ for 8 weeks. There was no placebo group; it did not demonstrate cognitive efficacy or CRP/LDL reductions.
There was no placebo group; self-reported change from baseline is not causal efficacy. This open study does not establish general cognitive benefit, reduced CRP/LDL or combination safety.
Source 4 · Abstract read
Human randomized controlled trial
Tamakoshi et al. (2023) reported improvement on selected memory measures in a 12-week trial of PQQ disodium salt, 20 mg/day, versus placebo in adults aged 20–65; age-subgroup outcomes and timing differed.
The accessed abstract does not provide the sample size; none was added. Multiple tasks and age subgroups do not establish general cognitive benefit at every age or a personal dose. Authors include Mitsubishi Gas Chemical employees.
Source 5 · Abstract read
Human randomized controlled trial
In a 2024 trial, 34 older adults with mild cognitive impairment received hydrogen-producing minerals/PQQ mixture or placebo for 6 weeks. Serum BDNF rose within the active group from baseline (p=0.01), but the treatment×time interaction was not significant (p=0.14).
This is not a trial of pure PQQ or chemically “reduced PQQ”; it uses a two-component product. Serum BDNF is not brain BDNF. A secondary orientation finding and multiple measurements do not establish general cognitive efficacy or long-term safety.
Source 6 · Abstract read
Regulatory scientific assessment
EFSA (2017) assessed PQQ disodium salt named BioPQQ as safe under specified manufacturing/product conditions and proposed use up to 20 mg/day in healthy adults excluding pregnant and breastfeeding women.
This product-safety opinion is not cognitive-efficacy evidence or a personal dose recommendation for everyone. It notes that comprehensive renal assessment was absent from human studies. Presence in food does not establish supplement need, pregnancy safety or safe drug combinations.
Source 7 · Official summary read
2026-11-11 correction: Mouse liver, an open study and a controlled human trial were distinguished. The hydrogen-mineral/PQQ mixture’s BDNF result was bounded by its between-group test. EFSA’s opinion retained its product/population conditions; general half-life and unsupported human BDNF/mitochondria claims were removed.
What is PQQ?
PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.
Mechanism of Effect
Stites et al. (2006) studied dietary PQQ and liver mitochondrial amount and function, particularly in developing mice; some measurements changed with a PQQ-deprived diet.
Mouse liver and a special-diet model do not demonstrate increased mitochondria or BDNF in the human brain. This experiment does not establish human PQQ deficiency, an essential nutrient requirement or cognitive benefit.
Clinical Trials
Nakano et al. (2012) studied self-reported stress, fatigue and sleep in an open-label trial of 17 adults taking 20 mg/day PQQ for 8 weeks. There was no placebo group; it did not demonstrate cognitive efficacy or CRP/LDL reductions.
There was no placebo group; self-reported change from baseline is not causal efficacy. This open study does not establish general cognitive benefit, reduced CRP/LDL or combination safety.
Tamakoshi et al. (2023) reported improvement on selected memory measures in a 12-week trial of PQQ disodium salt, 20 mg/day, versus placebo in adults aged 20–65; age-subgroup outcomes and timing differed.
The accessed abstract does not provide the sample size; none was added. Multiple tasks and age subgroups do not establish general cognitive benefit at every age or a personal dose. Authors include Mitsubishi Gas Chemical employees.
In a 2024 trial, 34 older adults with mild cognitive impairment received hydrogen-producing minerals/PQQ mixture or placebo for 6 weeks. Serum BDNF rose within the active group from baseline (p=0.01), but the treatment×time interaction was not significant (p=0.14).
This is not a trial of pure PQQ or chemically “reduced PQQ”; it uses a two-component product. Serum BDNF is not brain BDNF. A secondary orientation finding and multiple measurements do not establish general cognitive efficacy or long-term safety.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
The 10–20 mg/day PQQ used in human studies is not an established safe dose for everyone. High-dose animal toxicity findings do not define a safe human threshold. An unreported interaction does not establish safe combined use. Pregnancy and breastfeeding safety data are insufficient; people taking medicines should discuss combined use with a health professional.
EFSA (2017) assessed PQQ disodium salt named BioPQQ as safe under specified manufacturing/product conditions and proposed use up to 20 mg/day in healthy adults excluding pregnant and breastfeeding women.
This product-safety opinion is not cognitive-efficacy evidence or a personal dose recommendation for everyone. It notes that comprehensive renal assessment was absent from human studies. Presence in food does not establish supplement need, pregnancy safety or safe drug combinations.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Mitochondria and Brain Energy: Mechanisms and Evidence
Explore CoQ10, PQQ, NMN and creatine research; mitochondrial mechanisms do not explain every cause of brain fog or guarantee supplement benefits.
Sources
- Stites T, et al. (2006). Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice. Journal of Nutrition, 136(2), 390–396. PubMed · PMID 16424117
- Rucker R, et al. (2009). Potential physiological importance of pyrroloquinoline quinone. Alternative Medicine Review, 14(3), 268–277. PubMed · PMID 19803551
- Misra HS, et al. (2012). Pyrroloquinoline-quinone and its versatile roles in biological processes. Journal of Biosciences, 37(2), 313–325. PubMed · PMID 22581337
- Nakano M, Yamamoto T, Okamura H, Tsuda A, Kowatari Y. (2012). Effects of Oral Supplementation with Pyrroloquinoline Quinone on Stress, Fatigue, and Sleep. Functional Foods in Health and Disease, 2(8), 307–324. https://doi.org/10.31989/ffhd.v2i8.81 Publisher record · DOI · Functional Food Center
- Tamakoshi M, et al. (2023). Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults. Food & function, 14(5), 2496-2501. https://doi.org/10.1039/d2fo01515c PubMed · PMID 36807425
- Baltic S, et al. (2024). The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a randomized controlled trial. The journal of nutrition, health & aging, 28(8), 100287. https://doi.org/10.1016/j.jnha.2024.100287 PubMed · PMID 38908296
- EFSA NDA Panel. (2017). Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. https://www.efsa.europa.eu/en/efsajournal/pub/5058 European Food Safety Authority
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.
Mouse liver and a special-diet model do not demonstrate increased mitochondria or BDNF in the human brain. This experiment does not establish human PQQ deficiency, an essential nutrient requirement or cognitive benefit.
Human studies have used 10–20 mg/day PQQ; this is not a personal dosing recommendation. Supplemental PQQ disodium salt is water-soluble; a requirement for fatty meals is unsupported.
This product-safety opinion is not cognitive-efficacy evidence or a personal dose recommendation for everyone. It notes that comprehensive renal assessment was absent from human studies. Presence in food does not establish supplement need, pregnancy safety or safe drug combinations.